Feb 13, 2025 5:00pm EST Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Feb 07, 2025 7:30am EST Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Oct 31, 2024 6:30am EDT Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Aug 14, 2024 4:05pm EDT Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Aug 07, 2024 7:00am EDT Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Jun 24, 2024 8:30am EDT Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Jun 13, 2024 7:00am EDT Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
May 16, 2024 7:00am EDT New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
